Diclofenac Potassium 50 mg + Paracetamol 325 mg + Chlorpheniramine Maleate 4 mg + Magnesium Trisilicate 100 mg Uncoated Tablet

Diclofenac Potassium 50 mg + Paracetamol 325 mg + Chlorpheniramine Maleate 4 mg + Magnesium Trisilicate 100 mg Uncoated Tablet is a uncoated tablet formulated with Diclofenac Potassium 50 mg + Paracetamol 325 mg + Chlorpheniramine Maleate 4 mg + Magnesium Trisilicate 100 mg. The active ingredient profile is Diclofenac Potassium; Paracetamol; Chlorpheniramine Maleate; Magnesium Trisilicate, placing the product in the multi-ingredient analgesic / antihistamine / antacid combination category. This is a multi-ingredient symptom-management formulation with pharmacologically different components, so the exact approved indication must be taken from the manufacturer’s product literature. The uncoated presentation is an oral solid-dosage form and should be described according to the approved finished-product specification. For website cataloguing, composition, strength, dosage form and release/coating characteristics should be displayed prominently and consistently. The description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and the prescriber’s judgement. Prescription status, precautions, interactions, adverse effects and dosing must be checked against the current approved product label before publication. Manufacturer, licence, storage, shelf-life, pack configuration and market-specific regulatory details should be added only from verified product documentation.